Risk factors for esophageal candidiasis in a large cohort of HIV-infected patients treated with nucleoside analogues.

Abstract

To assess the risk factors for esophageal candidiasis (EC), a cohort study and a case-control study were conducted using 1,368 French patients who were already participating in the Delta trial (which compared different types of antiretroviral therapy in HIV-infected patients) and who had no previous history of EC. During a median follow-up period of 19 months, 87 (6%) patients developed EC. The results of the cohort study showed an increased risk of EC associated with a low baseline CD4+ cell count (P<0.0001), a high baseline plasma HIV RNA level (P < 0.0001) and prior zidovudine therapy (P = 0.02) at entry to the study. The case-control study revealed an increased risk of EC in patients with a recent low CD4+ cell count (P < 0.0002), recent antibacterial chemotherapy (P = 0.01) and oral candidiasis (P < 0.05). Cotrimoxazole prophylaxis also increased the risk of EC (P = 0.04) in the case-control study.

• Authors: S Abgrall, I Charreau, V Joly, J Bloch, J Reynes, Delta Coordinating Committee
• Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 20 Issue 5 Pg. 346-9 (May 2001) ISSN: 0934-9723 [Print] Germany
• PMID: 11453597 (Publication Type: Journal Article)

Chemical References

• Anti-HIV Agents

Topics

• AIDS-Related Opportunistic Infections (epidemiology)
• Adolescent
• Adult
• Aged
• Anti-HIV Agents (therapeutic use)
• CD4 Lymphocyte Count
• Candidiasis (epidemiology)
• Candidiasis, Oral (epidemiology)
• Case-Control Studies
• Cohort Studies
• Esophageal Diseases (epidemiology)
• Female
• HIV Infections (drug therapy, immunology)
• Humans
• Male
• Middle Aged
• Proportional Hazards Models
• Risk Factors
• Viral Load